Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Income: 2012-2025

Historic Net Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.6 million.

  • Enanta Pharmaceuticals' Net Income rose 35.08% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 29.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 29.41% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Net Income stood at -$18.6 million, which was down 1.82% from -$18.3 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Net Income registered a high of -$18.3 million during Q2 2025, and its lowest value of -$39.1 million during Q2 2023.
  • Over the past 3 years, Enanta Pharmaceuticals' median Net Income value was -$28.1 million (recorded in 2023), while the average stood at -$27.5 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Net Income plummeted by 503.91% in 2021 and then surged by 42.00% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Net Income (Quarterly) stood at -$30.1 million in 2021, then grew by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then spiked by 33.28% to -$22.3 million in 2024, then soared by 35.08% to -$18.6 million in 2025.
  • Its Net Income was -$18.6 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$22.6 million in Q1 2025.